RudaCure, a company specializing in the development of treatments for sensory disorders, announced on the 3rd that its chronic pain treatment (RCI002) has been selected as a supported project by the Korea Drug Development Fund (KDDF), and that optimization research to derive a lead compound will now begin in earnest.
RudaCure's RCI002 is a compound that selectively inhibits the activity of TRPV1, a key target known for developing powerful non-narcotic analgesics. According to the company's preliminary research, the compound demonstrated TRPV1 inhibitory activity and reduced pain in chronic pain animal models. Unlike existing TRPV1 antagonists, it does not cause abnormal fever, offering excellent analgesic efficacy with no significant side effects, giving it high potential for development as a safe treatment.
In particular, the company expects synergistic effects for the optimization research of RCI002 through joint execution of this support project with the team of Professor Park Cheol-gyu at Gachon University College of Medicine — a specialist in pain treatment development who is participating as the lead institution.
Source: BioTimes (http://www.biotimes.co.kr)